Dural Sinus Stenting of Low Grade Dural Arteriovenous Fistulae (DAVF) for Pulsatile Tinnitus Treatment

The goal of this randomized trial to assess the angiographic efficacy of venous stenting in dural arteriovenous fistulae (DAVF) via improvment on Cognard's Classification as compared to no intervention at 6 months Participants belonging to experimental group will be treated using venous stenting. DAVF will be assessed by angiography at 6 months follow-up. Participants belonging to control group will be followed accordingly to standard of care (no treatment). After 6 months, control group patients can be treated by any means accordinlgly to standard of care.

Inclusion Criteria:Patient presenting invalidating pulsatile tinnitusPatient presenting with PT anatomically correlated with a DAVFType I or IIa DAVF on digital subtraction angiography (DSA), according to Cognard's classification.DAVF located on sigmoid , lateral or posterior longitudinal sinus.Highly effective contraception for women of childbearing potential, maintained during research proceduresAffiliated or beneficiary of health insuranceSigned informed consentExclusion Criteria:Patient with DAVF not eligible for endovascular treatment .DAVF classification of IIb or more according to Cognard's classification.DAVF with severe sinus stenosis or occlusion judged as nor eligible for sinus stenting.DAVF showing evidence of recent (inferior to 3 months) thrombophlebitis at the site of fistulous dural sinus.Patient with DAVF previously treated with surgery or radiotherapy.Patient with multiple DAVFControlateral sinus aplasia or occlusionPatient presenting contra-indication to the use of LEA according to the instructions For Use.Patient participating in another clinical study evaluating another medical device,Any condition or any situation that would prohibit the patient from coming to the investigational center for the follow-up as recommended by the study protocol at 6 months.Patient with any known allergy to heparin, acetylsalicylic acid, Coumadin , Warfarin or other antiplatelet medicationsPatient has undergone a surgery including endovascular procedures in the last 30 days prior to the study procedure.Patient has had an Intracranial hemorrhage and/or subarachnoid hemorrhage in the past 30 days prior to the study procedureKnown serious sensitivity to radiographic contrast agents.Known sensitivity to nickel, titanium metals, or their alloysKnown renal failure as defined by a serum creatinine > 2.5 mg/dl (or 220 μmol/l) or glomerular filtration rate (GFR) < 30.Patient who has a contraindication to MRI or angiography for whatever reasonWomen who are pregnant, lactating, or who are planning to become pregnant during the anticipated study periodPatient unable to understand the nature, risks, significance and implications of the clinical investigation or unwilling to provide written informed consentPatient under legal protection